Oncolytics Biotech, Inc. (ONCY)
0.804
0.00 (0.00%)
USD |
NASDAQ |
May 19, 13:12
Oncolytics Biotech Research and Development Expense (Quarterly) : 4.552M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Gilead Sciences, Inc. | 1.354B |
| Karyopharm Therapeutics, Inc. | 33.78M |
| Replimune Group, Inc. | 52.87M |
| Sensei Biotherapeutics, Inc. | 2.536M |
| Tango Therapeutics, Inc. | 33.07M |